| Name | Title | Contact Details |
|---|
Korro Bio is an RNA editing company focused on the discovery and development of a new class of precision genetic medicines for both rare and common diseases. The company`s proprietary and modular platform, OPERA™ (Oligonucleotide promoted editing of RNA), builds on a deep understanding of ADAR biology, and combines data-driven design, oligo discovery and chemistry with clinically validated delivery vehicles, to achieve highly selective RNA editing. This unique technology enables the development of RNA editing therapeutics that deliver the functional benefits of gene therapy with a reversible, transient, titratable and specific treatment regimen, offering the potential to propel genetic medicine beyond rare genetic diseases into larger patient populations with common diseases. Korro is based in Cambridge, Mass.
LTZ Therapeutics is an immunotherapy-focused biotech company to develop novel therapies to improve clinical outcomes in patients with cancer and other diseases with an unmet clinical need.
Aerpio Therapeutics is a Cincinnati, OH-based company in the Healthcare, Pharmaceuticals, and Biotech sector. Aerpio Therapeutics is a biopharmaceutical company focused on the development of novel therapeutics for vascular disorders with a concentration on diseases of the eye.
Thrasos is a private, clinical-stage biotherapeutics company focused on delivering new solutions to individuals affected by kidney disease. The company's lead compound, THR-184 is currently being evaluated in a Phase 2 clinical study for the prevention of AKI in patients undergoing cardiac surgery. Thrasos is also developing compounds for diabetic nephropathy, a major cause of chronic kidney disease
Vividion Therapeutics, Inc. is a biotechnology company focused on transforming the future of human health through the creation of highly selective small molecule medicines that drug traditionally inaccessible targets. The company is advancing a broad, diversified pipeline of multiple, selective small molecule therapeutics for highly sought-after disease-causing target proteins in oncology and immunology. The company`s cutting-edge platform was spun out of the labs of Vividion`s scientific founders, a team of experts in chemical biology and synthetic chemistry from The Scripps Research Institute in La Jolla, CA.